Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel

William J. Trickler, Daniel J. Munt, Neha Jain, Shantaram S. Joshi, Alekha K. Dash

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: This investigation compared the tumor distribution, efficacy, blood pharmacokinetic parameters and hematological alterations following treatment with chitosan/glyceryl-monooleate (GMO) nanostructures containing paclitaxel (PTX) to a conventional formulation of PTX (Taxol®) in BALB/c female mice. Materials & methods: The tumor and blood concentrations of PTX were evaluated by HPLC and the pharmacokinetic parameters were determined through noncompartmental methods. Tumor development was evaluated by histopathological methods and hematological composition was monitored through differential white blood cells counts. Results: Lower localized or intravenous doses of PTX-chitosan/GMO nanostructures significantly increased the antitumor activity of paclitaxel. The tumor distribution studies showed effective concentrations in the tumors with the chitosan/GMO formulation while systemic blood levels remained lower than after administration of the conventional formulation. Conclusion: Delivery systems consisting of chitosan/GMO and PTX are safe and effective administered locally (intratumorally) or intravenously.

Original languageEnglish
Pages (from-to)437-448
Number of pages12
JournalNanomedicine
Volume6
Issue number3
DOIs
StatePublished - Apr 2011

Fingerprint

Pharmacokinetics
Nanostructures
Chitosan
Paclitaxel
tumor
Tumors
Blood
blood
Neoplasms
Cells
monoolein
distribution
pharmacokinetics
Leukocyte Count
High Pressure Liquid Chromatography
Chemical analysis
method

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel. / Trickler, William J.; Munt, Daniel J.; Jain, Neha; Joshi, Shantaram S.; Dash, Alekha K.

In: Nanomedicine, Vol. 6, No. 3, 04.2011, p. 437-448.

Research output: Contribution to journalArticle

Trickler, William J. ; Munt, Daniel J. ; Jain, Neha ; Joshi, Shantaram S. ; Dash, Alekha K. / Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel. In: Nanomedicine. 2011 ; Vol. 6, No. 3. pp. 437-448.
@article{4216e8cb5d9a42c3909bcd5dab335e1f,
title = "Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel",
abstract = "Aims: This investigation compared the tumor distribution, efficacy, blood pharmacokinetic parameters and hematological alterations following treatment with chitosan/glyceryl-monooleate (GMO) nanostructures containing paclitaxel (PTX) to a conventional formulation of PTX (Taxol{\circledR}) in BALB/c female mice. Materials & methods: The tumor and blood concentrations of PTX were evaluated by HPLC and the pharmacokinetic parameters were determined through noncompartmental methods. Tumor development was evaluated by histopathological methods and hematological composition was monitored through differential white blood cells counts. Results: Lower localized or intravenous doses of PTX-chitosan/GMO nanostructures significantly increased the antitumor activity of paclitaxel. The tumor distribution studies showed effective concentrations in the tumors with the chitosan/GMO formulation while systemic blood levels remained lower than after administration of the conventional formulation. Conclusion: Delivery systems consisting of chitosan/GMO and PTX are safe and effective administered locally (intratumorally) or intravenously.",
author = "Trickler, {William J.} and Munt, {Daniel J.} and Neha Jain and Joshi, {Shantaram S.} and Dash, {Alekha K.}",
year = "2011",
month = "4",
doi = "10.2217/nnm.10.135",
language = "English",
volume = "6",
pages = "437--448",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel

AU - Trickler, William J.

AU - Munt, Daniel J.

AU - Jain, Neha

AU - Joshi, Shantaram S.

AU - Dash, Alekha K.

PY - 2011/4

Y1 - 2011/4

N2 - Aims: This investigation compared the tumor distribution, efficacy, blood pharmacokinetic parameters and hematological alterations following treatment with chitosan/glyceryl-monooleate (GMO) nanostructures containing paclitaxel (PTX) to a conventional formulation of PTX (Taxol®) in BALB/c female mice. Materials & methods: The tumor and blood concentrations of PTX were evaluated by HPLC and the pharmacokinetic parameters were determined through noncompartmental methods. Tumor development was evaluated by histopathological methods and hematological composition was monitored through differential white blood cells counts. Results: Lower localized or intravenous doses of PTX-chitosan/GMO nanostructures significantly increased the antitumor activity of paclitaxel. The tumor distribution studies showed effective concentrations in the tumors with the chitosan/GMO formulation while systemic blood levels remained lower than after administration of the conventional formulation. Conclusion: Delivery systems consisting of chitosan/GMO and PTX are safe and effective administered locally (intratumorally) or intravenously.

AB - Aims: This investigation compared the tumor distribution, efficacy, blood pharmacokinetic parameters and hematological alterations following treatment with chitosan/glyceryl-monooleate (GMO) nanostructures containing paclitaxel (PTX) to a conventional formulation of PTX (Taxol®) in BALB/c female mice. Materials & methods: The tumor and blood concentrations of PTX were evaluated by HPLC and the pharmacokinetic parameters were determined through noncompartmental methods. Tumor development was evaluated by histopathological methods and hematological composition was monitored through differential white blood cells counts. Results: Lower localized or intravenous doses of PTX-chitosan/GMO nanostructures significantly increased the antitumor activity of paclitaxel. The tumor distribution studies showed effective concentrations in the tumors with the chitosan/GMO formulation while systemic blood levels remained lower than after administration of the conventional formulation. Conclusion: Delivery systems consisting of chitosan/GMO and PTX are safe and effective administered locally (intratumorally) or intravenously.

UR - http://www.scopus.com/inward/record.url?scp=79955596913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955596913&partnerID=8YFLogxK

U2 - 10.2217/nnm.10.135

DO - 10.2217/nnm.10.135

M3 - Article

VL - 6

SP - 437

EP - 448

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 3

ER -